Your browser doesn't support javascript.
loading
Advances in glioblastoma multiforme: Integrating therapy and pathology perspectives.
Shahcheraghi, Seyed Hossein; Alimardani, Maliheh; Lotfi, Malihe; Lotfi, Marzieh; Uversky, Vladimir N; Guetchueng, Stephanie Tamdem; Palakurthi, Sushesh Shrivastsa; Charbe, Nitin B; Hromic-Jahjefendic, Altijana; Aljabali, Alaa A A; Gadewar, Manoj M; Malik, Sumira; Goyal, Rohit; El-Tanani, Mohamed; Mishra, Vijay; Mishra, Yachana; Tambuwala, Murtaza M.
Afiliação
  • Shahcheraghi SH; Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Alimardani M; Medical Genetics Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad Univ
  • Lotfi M; Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Lotfi M; Abortion Research Center, Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Uversky VN; Department of Molecular Medicine and USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • Guetchueng ST; Institute of Medical Research and Medicinal Plants Studies, Ministry of Scientific Research and Innovation, PO Box 6163, Yaoundé, Cameroon.
  • Palakurthi SS; Department of Pharmaceutical Sciences, Irma Lerma Rangel School Of Pharmacy, Texas A&M University, Kingsville, TX 78363, USA.
  • Charbe NB; Center for Pharmacometrics & Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Hromic-Jahjefendic A; Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka cesta 15, Sarajevo 71000, Bosnia and Herzegovina.
  • Aljabali AAA; Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid, Jordan.
  • Gadewar MM; Department of Pharmacology, School of medical and allied sciences, K.R. Mangalam University, Gurgaon, Haryana 122103, India.
  • Malik S; Amity Institute of Biotechnology, Amity University Jharkhand, Ranchi, India.
  • Goyal R; School of Pharmaceutical Sciences, Shoolini University of Biotechnology & Management Sciences, Solan, India.
  • El-Tanani M; Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
  • Mishra V; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.
  • Mishra Y; Department of Zoology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab 144411, India.
  • Tambuwala MM; Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates; Lincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK. Electronic address: mtambuwala@lincoln.ac.uk.
Pathol Res Pract ; 257: 155285, 2024 May.
Article em En | MEDLINE | ID: mdl-38653089
ABSTRACT
Glioblastoma, a highly lethal form of brain cancer, is characterized by its aggressive growth and resistance to conventional treatments, often resulting in limited survival. The response to therapy is notably influenced by various patient-specific genetic factors, underscoring the disease's complexity. Despite the utilization of diverse treatment modalities such as surgery, radiation, and chemotherapy, many patients experience local relapse, emphasizing the critical need for improved therapeutic strategies to effectively target these formidable tumors. Recent years have witnessed a surge in interest in natural products derived from plants, particularly alkaloids, for their potential anticancer effects. Alkaloids have shown promise in cancer chemotherapy by selectively targeting crucial signaling pathways implicated in tumor progression and survival. Specifically, they modulate the NF-κB and MAPK pathways, resulting in reduced tumor growth and altered gene expression across various cancer types. Additionally, alkaloids exhibit the capacity to induce cell cycle arrest, further impeding tumor proliferation in several malignancies. This review aims to delineate recent advances in understanding the pathology of glioblastoma multiforme (GBM) and to explore the potential therapeutic implications of alkaloids in managing this deadly disease. By segregating discussions on GBM pathology from those on alkaloid-based therapies, we provide a structured overview of the current challenges in GBM treatment and the promising opportunities presented by alkaloid-based interventions. Furthermore, we briefly discuss potential future directions in GBM research and therapy beyond alkaloids, including emerging treatment modalities or areas of investigation that hold promise for improving patient outcomes. In conclusion, our efforts offer hope for enhanced outcomes and improved quality of life for GBM patients through alkaloid-based therapies. By integrating insights from pathology and therapeutic perspectives, we underscore the significance of a comprehensive approach in addressing this devastating disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article